You are here: Industry Insights > Market News > NMPA releases 2nd group of key projects for China’s drug regulatory science action plan

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

Avatrombopag Maleate

BioHub® Magnetic Separator

Avatrombopag

Ursodeoxycholic acid

Troxerutin

CytoLinX® BRTF Single-use Top-driven Bioreactor Bag

NMPA releases 2nd group of key projects for China’s drug regulatory science action plan

October 25, 2021

Tag: NMPA , drug regulatory , products

Favorites

The National Medical Products Administration (NMPA) issued a list of the second group of key projects for China's drug regulatory science action plan based on the summary of the implementation of the first group on June 24.

Departments and related affiliated institutions of the NMPA were urged to speedily formulate implementation plans in accordance with related requirements and to further improve their drug regulatory capacities, so as to speed up the marketization of innovative products and better meet the needs of public health.

Previous:Emergency Physicians: We Must Address Vaccine Hesitancy, Correct Misinformation to End Pandemic

Next:Phlow receives approval to join BARDA CDMO network

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

PharmaSourcesNovember 22, 2024

Sartorius Stedim Biotech, a leading partner of the biopharmaceutical industry, today opened its new Center for Bioprocess Innovation in Marlborough, Massachusetts.

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

NMPA releases 2nd group of key projects for China’s drug regulatory science action plan | Pharmasources.com

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Discover how AI in pharmacovigilance improves drug safety by predicting risks, identifying harmful interactions, and enhancing patient outcomes.

You may like
More>>

Chinese Lab Water Cooling Products 50L -40℃ Air Cooled Chillers

new products plastic packaging bottle biodegradable pharmaceutical chemical medical

sterility test for pharmaceutical products

Specializing in the production of plastic products, plastic trays, food trays, electronic hardware e

1%-10% Withanolide Ashwagandha Extract for Healthcare Products

biological products vegetable protein instant solid beverage Wheat extract milk spray drying machine

SODA Spray Dryer for Pharmaceutical and Food Products

Pharmaceutical vials for health products

FFE Multi Row Products Packing Machine

High Quality Cyclomethicone CAS 69430-24-6 /Cyclodimethylsiloxanes for Hair Care Products

NMPA releases 2nd group of key projects for China’s drug regulatory science action plan

Related News

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

You may likeMore>>

You may like
More>>